These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27557121)

  • 1. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
    Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
    PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Chang K; Zhang B; Guo X; Zong M; Rahman R; Sanchez D; Winder N; Reardon DA; Zhao B; Wen PY; Huang RY
    Neuro Oncol; 2016 Dec; 18(12):1680-1687. PubMed ID: 27257279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
    Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
    Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
    J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
    Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM; Hovey EJ; Wheeler H
    Cancer; 2017 Sep; 123(18):3576-3582. PubMed ID: 28678383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
    Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
    Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
    Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
    Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
    Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
    Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
    Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
    Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
    Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma.
    Pérez-Beteta J; Molina-García D; Martínez-González A; Henares-Molina A; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; Martino J; Velásquez C; Meléndez-Asensio B; de Lope ÁR; Moreno R; Barcia JA; Asenjo B; Benavides M; Herruzo I; Lara PC; Cabrera R; Albillo D; Navarro M; Pérez-Romasanta LA; Revert A; Arana E; Pérez-García VM
    Eur Radiol; 2019 Apr; 29(4):1968-1977. PubMed ID: 30324390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.